Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment

Ann Tempel, R. Suzanne Zukin, Eliot L. Gardner

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Chronic administration of the narcotic antagonist naltrexone resulted in a marked increase in brain opiate receptors. Similar changes were observed for putative Mu, Delta, and Kappa opiate receptor subtypes. In contrast, only a modest increase was observed for the putative Sigma receptor. Withdrawal from chronic naltrexone treatment resulted in a decrease from elevated receptor levels to nearly control receptors levels in a period of about 6 days, as revealed by [3H] etorphine binding. These results may shed light on the mechanisms of opiate dependence and withdrawal.

Original languageEnglish (US)
Pages (from-to)1401-1404
Number of pages4
JournalLife Sciences
Volume31
Issue number12-13
DOIs
StatePublished - 1982

Fingerprint

Naltrexone
Opioid Receptors
Opiate Alkaloids
Brain
Etorphine
sigma Receptors
Opioid-Related Disorders
kappa Opioid Receptor
Narcotic Antagonists

ASJC Scopus subject areas

  • Pharmacology

Cite this

Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. / Tempel, Ann; Zukin, R. Suzanne; Gardner, Eliot L.

In: Life Sciences, Vol. 31, No. 12-13, 1982, p. 1401-1404.

Research output: Contribution to journalArticle

Tempel, Ann ; Zukin, R. Suzanne ; Gardner, Eliot L. / Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. In: Life Sciences. 1982 ; Vol. 31, No. 12-13. pp. 1401-1404.
@article{e74fffd7ef68442dbdd4e4755095e857,
title = "Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment",
abstract = "Chronic administration of the narcotic antagonist naltrexone resulted in a marked increase in brain opiate receptors. Similar changes were observed for putative Mu, Delta, and Kappa opiate receptor subtypes. In contrast, only a modest increase was observed for the putative Sigma receptor. Withdrawal from chronic naltrexone treatment resulted in a decrease from elevated receptor levels to nearly control receptors levels in a period of about 6 days, as revealed by [3H] etorphine binding. These results may shed light on the mechanisms of opiate dependence and withdrawal.",
author = "Ann Tempel and Zukin, {R. Suzanne} and Gardner, {Eliot L.}",
year = "1982",
doi = "10.1016/0024-3205(82)90391-5",
language = "English (US)",
volume = "31",
pages = "1401--1404",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "12-13",

}

TY - JOUR

T1 - Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment

AU - Tempel, Ann

AU - Zukin, R. Suzanne

AU - Gardner, Eliot L.

PY - 1982

Y1 - 1982

N2 - Chronic administration of the narcotic antagonist naltrexone resulted in a marked increase in brain opiate receptors. Similar changes were observed for putative Mu, Delta, and Kappa opiate receptor subtypes. In contrast, only a modest increase was observed for the putative Sigma receptor. Withdrawal from chronic naltrexone treatment resulted in a decrease from elevated receptor levels to nearly control receptors levels in a period of about 6 days, as revealed by [3H] etorphine binding. These results may shed light on the mechanisms of opiate dependence and withdrawal.

AB - Chronic administration of the narcotic antagonist naltrexone resulted in a marked increase in brain opiate receptors. Similar changes were observed for putative Mu, Delta, and Kappa opiate receptor subtypes. In contrast, only a modest increase was observed for the putative Sigma receptor. Withdrawal from chronic naltrexone treatment resulted in a decrease from elevated receptor levels to nearly control receptors levels in a period of about 6 days, as revealed by [3H] etorphine binding. These results may shed light on the mechanisms of opiate dependence and withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=0020463792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020463792&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(82)90391-5

DO - 10.1016/0024-3205(82)90391-5

M3 - Article

VL - 31

SP - 1401

EP - 1404

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 12-13

ER -